InvestorsObserver is giving Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) an Analyst Rating Rank of 79, meaning BIO is ranked higher by analysts than 79% of stocks. The average projection by analysts for BIO is $560 over the next 12 months and analyst’s classify the stock as a Strong Buy
Why are Analyst Ratings Important?
Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve.
InvestorsObserver combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.
What's Happening With Bio-Rad Laboratories, Inc. Class A Common Stock Stock Today?
Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) stock is up 2.21% while the S&P 500 is down -0.25% as of 11:02 AM on Wednesday, Nov 25. BIO is higher by $11.40 from the previous closing price of $516.56 on volume of 43,713 shares. Over the past year the S&P 500 is higher by 15.47% while BIO is higher by 42.12%. BIO earned $116.78 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 4.53.
Click Here to get the full report on Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) Stock.
